BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...Everest in the future.Beyond Trodelvy, the company’s pipeline includes assets in infectious disease, immunology and cardio-renal...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

...Across the 28, 50 and 70 mg dose groups, the company also reported improvements in cardio-metabolic...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...also delivers an exit to an investor syndicate that has poured $86 million into the cardio-renal...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Growth-accommodating biomimetic prosthetic valves for congenital valve disease

...School, Boston, Mass. email: sophie.hofferberth@cardio.chboston.org CONTACT: Pedro J. del Nido, same affiliation as above email: pedro.delnido@cardio.chboston.org Claire...
BioCentury | Apr 1, 2020
Finance

Pandion’s immune-regulating platform attracts $80M B round

...CEO Rahul Kakkar founded and served as CMO and chief strategy officer of cardiovascular and cardio-renal...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...added the fund was particularly interested in investing in companies working on products for CNS, cardio-metabolic...
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...experienced complement activation, thrombocytopenia, a dip in red blood cell count, acute kidney injury and cardio-pulmonary...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...of its offering, which was expected to price ahead of Wednesday’s session. The liver and cardio-metabolic...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...Third Pole Therapeutics Inc. said Bill Athenson will succeed David Zapol as CEO. Zapol, the cardio-pulmonary...
BioCentury | Jul 19, 2019
Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

...of life or symptoms is extremely important,” Kleinhans told BioCentury. LSP’s heart failure companies include Cardio...
Items per page:
1 - 10 of 233
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...Everest in the future.Beyond Trodelvy, the company’s pipeline includes assets in infectious disease, immunology and cardio-renal...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

...Across the 28, 50 and 70 mg dose groups, the company also reported improvements in cardio-metabolic...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...also delivers an exit to an investor syndicate that has poured $86 million into the cardio-renal...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Growth-accommodating biomimetic prosthetic valves for congenital valve disease

...School, Boston, Mass. email: sophie.hofferberth@cardio.chboston.org CONTACT: Pedro J. del Nido, same affiliation as above email: pedro.delnido@cardio.chboston.org Claire...
BioCentury | Apr 1, 2020
Finance

Pandion’s immune-regulating platform attracts $80M B round

...CEO Rahul Kakkar founded and served as CMO and chief strategy officer of cardiovascular and cardio-renal...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...added the fund was particularly interested in investing in companies working on products for CNS, cardio-metabolic...
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...experienced complement activation, thrombocytopenia, a dip in red blood cell count, acute kidney injury and cardio-pulmonary...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...of its offering, which was expected to price ahead of Wednesday’s session. The liver and cardio-metabolic...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...Third Pole Therapeutics Inc. said Bill Athenson will succeed David Zapol as CEO. Zapol, the cardio-pulmonary...
BioCentury | Jul 19, 2019
Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

...of life or symptoms is extremely important,” Kleinhans told BioCentury. LSP’s heart failure companies include Cardio...
Items per page:
1 - 10 of 233